Fastox to Present its Long-Lasting Botulinum Toxin LAST Technology
Swiss biotech Fastox Pharma will present for the first time its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins from July 27-30 in New Orleans, LA.
Fastox has discovered that combining botulinum toxin type A (BoNT/A) with fast-acting myorelaxant drugs could accelerate BoNT/A onset of action, but, most importantly and surprisingly, could also significantly increase its duration of action. Pre-clinical results on such combination will be presented including mechanism of action.
Increasing BoNT/A duration of action is a long-awaited innovation in the $5.5 billion BoNT/A aesthetic and therapeutic markets. The LAST technology, validated in preclinical models, will fulfill this unmet need. Fastox plans to start first-in-human Phase 1/2 trial early next year.
Fastox VP Innovation, Mickaël Machicoane, PhD, said “I am honored to present our discovery at the Toxins 2022 International Conference towards renowned experts from all over the globe. I will notably shed light on the mechanism of action of our LAST technology, that has been dissected through a fruitful collaboration with the Neuroparalysis and Neuroregeneration Laboratory of the University of Padova.”
The poster will be presented on site and available during 6 months after the conference in the Toxicon journal.
The latest developments in the basic science and clinical applications of neurotoxins are presented at the TOXINS conferences. More information can be found at TOXINS 2022 | International Neurotoxin Association (neurotoxins.org).
Fastox is a Swiss privately owned biotechnology company created by seasoned experts in biotech and botulinum neurotoxins. Fastox researches and develops drugs boosting botulinum toxin performances for both aesthetic and therapeutic applications. Fastox is a Remora venture (ww.remora-biotech.ch) headquartered in Lausanne, Switzerland. For more information, visit Home | Fastox Pharma
Fastox proprietary LAST (Long-Acting Strengthened Toxin) technology allows to boost the performance of botulinum toxins A by combining them with safe myorelaxant drugs. The LAST technology has been validated in preclinical models and has shown to significantly increase the BoNT duration of action. Fastox plans the first-in-human Phase 1/2 trial early next year with its lead candidate FTP-501.
Total Page Views: 1113
